TrialJournal of clinical pharmacology2017

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.

Jonathan Q Tran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.